Page last updated: 2024-08-22

lanthanum and Kidney Diseases

lanthanum has been researched along with Kidney Diseases in 32 studies

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's20 (62.50)29.6817
2010's11 (34.38)24.3611
2020's1 (3.13)2.80

Authors

AuthorsStudies
Fujii, H; Goto, S; Kono, K; Nishi, S; Watanabe, K1
Hutchison, AJ; Laville, M1
Anger, M; Fishbane, S; Martin, KJ; Mehrotra, R; Sprague, SM; Zeig, S1
Pratt, RD; Smyth, MD1
Valdivieso, JM1
Fernandez Giraldez, E; Sánchez González, MC; Valdivielso Revilla, JM1
Spasovski, G1
Abboud, H; Dauphin, M; Finn, W; Qiu, P; Sprague, SM; Zhang, P1
Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J1
Koiwa, F; Sato, Y1
Joki, N1
Shigematsu, T; Tatsuta, K1
Kazama, JJ1
Taniguchi, M1
Kadowaki, D; Maruyama, T1
Ketteler, M1
Fitchett, D; Jamal, SA; Lok, CE; Mendelssohn, DC; Tsuyuki, RT1
D'Haese, P; Damment, SJ1
Orita, H; Shigematsu, T; Tanaka, Y; Yamanaka, S; Yoshimoto, W1
Yokoyama, K1
Negi, S; Shigematsu, T1
Kerr, PG; Lau, KK; Polkinghorne, KR; Toussaint, ND1
Flanagan, RJ; Handley, SA; Raja, KB; Sharpe, C1
Campbell, SB; Hawley, CM; Isbel, NM; Johnson, DW; Mudge, DW; Petrie, JJ; van Eps, CL1
Akizawa, T; Mizobuchi, M; Nakazawa, A1
Flanigan, M; Haynes, WG; Kalil, RS; Stanford, W1
Hamano, T1
Hanba, Y; Masumoto, A; Moribata, M; Shigemathu, T1
Cases, A1
Brooks, T; Candiani, C; Hudson, JQ; Joy, MS; Kshirsagar, A1
Aime, S; Canavese, C; Stratta, P1
Brancaccio, D; Cozzolino, M; Fallabrino, G; Galassi, A; Gallieni, M; Pasho, S1

Reviews

19 review(s) available for lanthanum and Kidney Diseases

ArticleYear
[Experimental advances in mineral metabolism].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2008, Volume: 28 Suppl 5

    Topics: Animals; Calcinosis; Calcium; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Chronic Disease; Drug Evaluation, Preclinical; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Intestinal Absorption; Kidney; Kidney Diseases; Lanthanum; Phosphorus; Sodium-Phosphate Cotransporter Proteins

2008
[Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2008, Volume: 28 Suppl 5

    Topics: Calcifediol; Calcinosis; Calcitriol; Cardiovascular Diseases; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphorus; Polyamines; Prevalence; Renal Dialysis; Sevelamer; Vitamin D; Vitamin D Deficiency

2008
New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease.
    Recent patents on cardiovascular drug discovery, 2008, Volume: 3, Issue:3

    Topics: Calcinosis; Cardiovascular Diseases; Chronic Disease; Humans; Kidney Diseases; Lanthanum; Minerals; Parathyroid Hormone; Phosphates; Polyamines; Sevelamer

2008
[Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
    Clinical calcium, 2009, Volume: 19, Issue:2

    Topics: Administration, Oral; Aluminum Compounds; Calcium Carbonate; Chronic Disease; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D

2009
[Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate].
    Clinical calcium, 2009, Volume: 19, Issue:2

    Topics: Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Renal Dialysis; Tissue Distribution

2009
[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].
    Clinical calcium, 2009, Volume: 19, Issue:2

    Topics: Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Randomized Controlled Trials as Topic

2009
[Is lanthanum carbonate a safe drug?].
    Clinical calcium, 2009, Volume: 19, Issue:2

    Topics: Administration, Oral; Chronic Disease; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum

2009
[Use of phosphate binder in predialysis patients].
    Clinical calcium, 2009, Volume: 19, Issue:2

    Topics: Calcium Carbonate; Chronic Disease; Dialysis; Drug Approval; Humans; Hyperphosphatemia; Japan; Kidney Diseases; Lanthanum; Polyamines; Prognosis; Sevelamer

2009
[To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients].
    Clinical calcium, 2009, Volume: 19, Issue:2

    Topics: Chronic Disease; Drug Administration Schedule; Hyperphosphatemia; Kidney Diseases; Lanthanum; Patient Compliance; Patient Education as Topic; Polyamines; Sevelamer

2009
The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
    The International journal of artificial organs, 2009, Volume: 32, Issue:2

    Topics: Chelating Agents; Chronic Disease; Fibroblast Growth Factor-23; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Polyamines; Renal Dialysis; Sevelamer

2009
The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:10

    Topics: Acetates; Calcium Carbonate; Calcium Compounds; Cause of Death; Chelating Agents; Chronic Disease; Humans; Kidney Diseases; Lanthanum; Polyamines; Sevelamer

2009
[Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients].
    Clinical calcium, 2010, Volume: 20, Issue:5

    Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Chronic Disease; Contraindications; Dialysis; Diphosphonates; Fractures, Spontaneous; Kidney Diseases; Lanthanum; Minerals; Polyamines; Sevelamer

2010
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
    Clinical calcium, 2010, Volume: 20, Issue:7

    Topics: Bone Density; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Dialysis; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Practice Guidelines as Topic

2010
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Clinical calcium, 2010, Volume: 20, Issue:7

    Topics: Cardiovascular Diseases; Chronic Disease; Drug Design; Hyperphosphatemia; Kidney Diseases; Lanthanum; Renal Dialysis; Risk

2010
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].
    Clinical calcium, 2011, Volume: 21, Issue:12

    Topics: Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Lanthanum; Membrane Proteins; Naphthalenes; Vascular Calcification; Vitamin D

2011
[Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].
    Clinical calcium, 2012, Volume: 22, Issue:7

    Topics: Bone Diseases, Metabolic; Carbamates; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit Analysis; Humans; Kidney Diseases; Lanthanum; Minerals; Naphthalenes; Parathyroidectomy; Polyamines; Sevelamer; Vitamin D

2012
[Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Clinical calcium, 2012, Volume: 22, Issue:7

    Topics: Aluminum Hydroxide; Calcium Carbonate; Chelating Agents; Cholestyramine Resin; Chronic Disease; Diet, Protein-Restricted; Drug Design; Humans; Hyperphosphatemia; Ion Exchange Resins; Kidney Diseases; Lanthanum; Phosphorus, Dietary; Polyamines; Sevelamer

2012
Lanthanum carbonate.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:2

    Topics: Animals; Chronic Disease; Clinical Trials as Topic; Humans; Kidney Diseases; Lanthanum; Phosphorus; Treatment Outcome

2006
Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
    Contributions to nephrology, 2008, Volume: 161

    Topics: Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D

2008

Trials

5 trial(s) available for lanthanum and Kidney Diseases

ArticleYear
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:11

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Calcium; Canada; Chronic Disease; Dose-Response Relationship, Drug; Europe; Female; Humans; Hyperphosphatemia; Israel; Kidney Diseases; Lanthanum; Male; Middle Aged; Outcome Assessment, Health Care; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Treatment Outcome

2008
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
    Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Drug Administration Schedule; Female; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphorus; Renal Dialysis; Tablets; Time Factors; Treatment Outcome; United States

2008
Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
    Clinical journal of the American Society of Nephrology : CJASN, 2009, Volume: 4, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Double-Blind Method; Female; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Severity of Illness Index; Time Factors; Treatment Outcome

2009
Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
    Nephrology (Carlton, Vic.), 2011, Volume: 16, Issue:3

    Topics: Adult; Aged; Aortic Diseases; Aortography; Biomarkers; Bone Density; Calcinosis; Calcium; Calcium Carbonate; Chelating Agents; Disease Progression; Female; Humans; Kidney Diseases; Lanthanum; Linear Models; Lumbar Vertebrae; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Victoria

2011
Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study.
    Clinical nephrology, 2012, Volume: 78, Issue:1

    Topics: Aged; Biomarkers; Brachial Artery; Calcium; Chelating Agents; Chronic Disease; Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Humans; Iowa; Kidney Diseases; Lanthanum; Middle Aged; Phosphorus; Pilot Projects; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome; Vascular Calcification; Vasodilation

2012

Other Studies

8 other study(ies) available for lanthanum and Kidney Diseases

ArticleYear
Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis.
    BMC cardiovascular disorders, 2020, 01-30, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Biomarkers; Calcinosis; Calcium Carbonate; Chelating Agents; Disease Progression; Female; Heart Valve Diseases; Humans; Kidney Diseases; Lanthanum; Male; Middle Aged; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Time Factors; Treatment Outcome

2020
Letter regarding 'Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate'.
    Kidney international, 2008, Volume: 74, Issue:4

    Topics: Chelating Agents; Contraindications; Contrast Media; Gadolinium; Humans; Kidney Diseases; Kidney Failure, Chronic; Lanthanum; United States; United States Food and Drug Administration; Uremia

2008
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD.
    American journal of physiology. Renal physiology, 2009, Volume: 296, Issue:4

    Topics: 3' Untranslated Regions; Adenine; Aniline Compounds; Animals; Calcium; Chronic Disease; Disease Models, Animal; Half-Life; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Male; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Phosphates; Phosphorus, Dietary; Propylamines; Rats; RNA Stability; RNA-Binding Proteins; RNA, Messenger; Time Factors; Trans-Activators

2009
Comment on 'Lanthanum deposition in a dialysis patient'.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:1

    Topics: Bone Diseases; Humans; Kidney Diseases; Lanthanum; Lymph Nodes; Mesentery; Renal Dialysis

2010
Measurement of serum lanthanum in patients treated with lanthanum carbonate by inductively coupled plasma-mass spectrometry.
    Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 2

    Topics: Adult; Aged; Blood Chemical Analysis; Drug Contamination; Female; Humans; Kidney Diseases; Lanthanum; Limit of Detection; Male; Mass Spectrometry; Middle Aged; Renal Dialysis; Reproducibility of Results

2011
Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?
    BMC nephrology, 2011, May-13, Volume: 12

    Topics: Aluminum; Bone Diseases; Chelating Agents; Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Polyamines; Renal Dialysis; Sevelamer

2011
The latest findings in basic and clinical nephrology science.
    Drug news & perspectives, 2005, Volume: 18, Issue:3

    Topics: Anemia; Cinacalcet; Clinical Trials as Topic; Humans; Kidney Diseases; Kidney Transplantation; Lanthanum; Naphthalenes; Renal Dialysis

2005
Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate.
    Kidney international, 2007, Volume: 72, Issue:9

    Topics: Chelating Agents; Contraindications; Fibrosis; Gadolinium; Humans; Kidney Diseases; Kidney Failure, Chronic; Lanthanum; Skin Diseases; United States; United States Food and Drug Administration; Uremia

2007